Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

By Kami McDonald, Student Pharmacist and Karen L. Kier, Pharmacist ONU Healthwise Pharmacy ...

Indianapolis: Eli Lilly and Company has announced that Anne White, executive vice president and president, Lilly Neuroscience ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly (LLY) stock in focus as the company's neuroscience chief Anne White retires, and the firm begins an executive ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...

Treatment with IV donanemab in early-stage Alzheimer’s disease demonstrated sustained clinical benefits for up to 3 years, with early initiation responsible for better outcomes, data from a long-term ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...